PCVX
Vaxcyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$61.06
−0.19%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.3x
Market Cap
$9.09B
MomentumView details →
1D Return
−0.19%
YTD Return
+32.39%
RSI (14)
56.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.3x
Market Cap
$9.09B
RSI (14)
56.1
MomentumView details →
1D Return
−0.19%
YTD Return
+32.39%
SummaryUpdated Jun 1, 2026
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology company founded in 2013 and headquartered in San Carlos, California. Originally incorporated as SutroVax, Inc., the company rebranded to Vaxcyte in May 2020 and went public in June 2020. Vaxcyte specializes in developing novel protein vaccines designed to prevent or treat bacterial infectious diseases, with a particular focus on pneumococcal infections and other serious bacterial pathogens that pose significant public health challenges.
Similar companies
Latest newsMore news →
Vaxcyte, Inc. appointed Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer, effective September 3, 2026.22h agoDeutsche Bank AG acquired a new minority stake in Vaxcyte, Inc., purchasing 258,338 shares valued at approximately $15.02 million, representing 0.18% ownership, as disclosed in an SEC filing.12d ago